Ligand Pharmaceuticals (LGND) Return on Sales (2010 - 2026)

Ligand Pharmaceuticals has disclosed Return on Sales across 16 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at Ligand Pharmaceuticals, down from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2025 to a low of 0.01% in Q1 2025.
• The 5-year median for Return on Sales is 0.0% (2022), against an average of 0.0%.
• Across the five-year window, Return on Sales fell 1 bps in 2024 and grew 1 bps in 2025, its largest moves.
• Ligand Pharmaceuticals' Return on Sales stood at 0.0% in 2022, then soared by 78 bps to 0.0% in 2023, then plunged by 5627 bps to 0.01% in 2024, then jumped by 203 bps to 0.01% in 2025, then sank by 134 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.